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ABSTRACT
Background: cJun terminal kinase (JNK) is constitutively
activated in most hepatocellular carcinomas (HCCs), yet
its exact role in carcinogenesis remains controversial.
While tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is known as a major mediator of
acquired immune tumour surveillance, and is currently
being tested in clinical trials as a novel cancer therapy,
the resistance of many tumours to TRAIL and concerns
about its toxicity in vivo represent obstacles to its clinical
application. In this study we investigated whether JNK
activity in HCC could contribute to the resistance to
apoptosis in these tumours.
Methods: The effect of JNK/Jun inhibition on receptor-
mediated apoptosis was analysed by pharmacological
inhibition or RNA interference in cancer cells and non-
tumour cells isolated from human liver or transgenic mice
lacking a phosphorylation site for Jun.
Results: JNK inhibition caused cell cycle arrest,
enhanced caspase recruitment, and greatly sensitised
HCC cells but not normal hepatocytes to TRAIL. TRAIL-
induced activation of JNK could be effectively interrupted
by administration of the JNK inhibitor SP600125.
Conclusions: Expression and TRAIL-dependent feedback
activation of JNK likely represent a mechanism by which
cancer cells escape TRAIL-mediated tumour surveillance.
JNK inhibition might represent a novel strategy for
specifically sensitising HCC cells to TRAIL thus opening
promising therapeutic perspectives for safe and effective
use of TRAIL in cancer treatment.
Hepatocellular carcinoma (HCC) is one of the
most common cancers worldwide, and its inci-
dence is rising. To date, surgery is the only curative
treatment available for those who qualify. The
majority of patients, however, are not suitable
candidates for surgery, and curative medical treat-
ment is currently not available. Therefore, new
therapeutic approaches are needed.1
Loss of sensitivity to apoptosis is a hallmark of
cancer. This is thought to occur through several
mechanisms including loss of the death receptors
TRAIL-R or CD95, or impairment of intracellular
signalling pathways.2 Previous studies demon-
strated enhanced primary tumour and metastases
formation in mice after TRAIL-receptor blockage
or in TRAIL-receptor knock-out mice;3 clinical
studies have furthermore shown a correlation
between loss of death receptors and dedifferentia-
tion, tumour size, poor prognosis, and tumour
recurrence.4 We have also recently shown that
over-expression of the TRAIL-binding soluble
decoy receptor osteoprotegerin (OPG) correlates
with tumour stage and metastasis formation in
patients affected by colon carcinoma.5 Activation
of apoptosis signalling pathways in cancer cells
otherwise resistant to apoptosis is therefore an
important therapeutic strategy.
Due to its ability to induce apoptosis in cancer cells
while leaving normal cells unharmed, TRAIL has
become a promising candidate for tumour therapy.6 7
While in vitro toxicity of TRAIL to non-tumour
tissues varies greatly, depending on the experimental
design and the type of TRAIL used,8 9 recent clinical
trials seem to confirm the safety of TRAIL adminis-
tration in vivo.10–12 In spite of these reassuring results,
concerns about the safety of systemic administration
of TRAIL remain, especially with regards to possible
toxic effects on diseased organs.13 14
A second, relevant, limitation to a therapeutic
use of TRAIL is the resistance of about 50% of
cancer cells to the activation of the receptor-
mediated apoptotic pathway.15
Consequently, a future clinical use of TRAIL will
have to confront the challenge of sensitising cancer
cells to this molecule as well as minimising its
cytotoxic effect on normal tissues. This prompts a
reconsideration of known carcinogenic signal path-
ways regarding their contribution to resistance to
receptor-mediated apoptosis.16–18
Through the phosphorylation of c-Jun and its
activating protein-1 (AP-1) transcription activity,
cJun N-terminal kinase (JNK) regulates a wide
spectrum of cellular activities in physiological
conditions and has been shown to act pro- and
anti-apoptotically in different cell types and
experimental systems19 20 (for a review, see the
excellent work by Czaja19). The fact that JNK
might play a role in the pathogenesis of tumours is
supported by the fact that this kinase is constitu-
tively expressed in several tumours and in most
hepatocellular carcinomas.21–25 The mechanisms
through which JNK signalling affects the patho-
genesis of tumours remain elusive, however.
We hypothesised that over-expression of JNK/
Jun in HCC contributes to the pathogenesis of
tumours by specifically interfering with receptor-
induced apoptosis. Targeting JNK might therefore
represent the key to the successful use of TRAIL as
a cancer treatment.
MATERIALS AND METHODS
Cell culture and siRNA tranfection
Chang, HepG2 and Huh7 cells were grown in
RPMI medium (PAA Laboratories, Pasching,
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Figure 1 JNK inhibition enhances TRAIL-R- and CD95-mediated apoptosis. Here all experiments were performed in Chang hepatoma cells. (A) Left
panel: apoptosis rates after treatment with SP600125 (SP, 20 mmol/l), anti-Apo1 (Apo, 500 ng/ml), TRAIL (at increasing concentrations of 1, 5, 10 and
25 ng/ml), or combination of SP600125 with anti-Apo1 or TRAIL. Protein A was added at 0.01 times the concentration of anti-Apo1 to facilitate cross-
linking of the antibody. DMSO 0.2% was used as control. 0.86105 Chang cells per well were seeded in 12-well plates. After overnight incubation, cells
were treated for 16 h as indicated. The bars indicate mean and SD of one representative experiment, performed in triplicate, and repeated at least three
times. Sub G1-events were measured by FACS analysis after propidium iodide stain. Asterisks designate statistical significances as calculated by the t
test, comparing apoptosis rates of cells stimulated with anti-Apo1 or TRAIL in combination with SP600125 vs cells treated with anti-Apo1 or TRAIL in
association with DMSO (p,0.001). Right panel: western blot analysis of phospho-c-Jun, c-Jun and actin (loading control) of same cells. 0.86106 cells
were seeded in 10 cm dishes. After overnight incubation, cells were treated with 20 mmol/l SP600125 or DMSO; where indicated 1 mmol of MMS was
added 30 min after SP600125 to induce c-Jun phosphorylation. 50 mg of total protein per lane were separated by SDS–PAGE. (B) Representative flow-
cytometry pattern of Chang cells shown in A (for TRAIL the FACS pattern of cells treated with 25 ng/ml is shown). (C) Cell cycle analysis of Chang cells
after treatment with DMSO or SP600125 for 24 h. The G2 cell cycle phase was higher in SP600125-treated cells vs cells treated with DMSO, while the
G1 and S phase remarkably lower (respective values: G2/M phase, 46.67 (SD 0.47) and 16.33 (SD 1.70), p,0.005; S phase, 16.0 (SD 0.82) and 25.33
(SD 1.25), p,0.01; G1 phase, 37.33 (SD 0.94) and 57.67 (SD 0.47), p,0.005). DMSO, dimethy sulfoxide; FACS, fluorescence-activated cell sorting;
JNK, cJun N-terminal kinase; MMS, methyl methan sulfonate; SP, SP600125; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
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Austria), HepA1-6 cells were cultured in DMEM (Gibco BRL,
Karlsruhe, Germany) supplemented with 10% fetal calf serum
(FCS) and 1% penicillin–streptomycin (Gibco BRL). Tissue
sample collection from human liver resections was performed
according to the guidelines of the charitable state-controlled
foundation Human Tissue and Cell Research (Regensburg,
Germany).26 Human hepatocytes were isolated using a modified
two-step EGTA/collagenase perfusion procedure as described
previously.27 Mouse hepatocytes were isolated from A/A mice,
lacking the phosphorylation site for c-Jun28 or from syngenic
wild-type mice. Cell viability, as determined by trypan blue
exclusion, was typically .90%. Cells were plated on 6-well
plates (56105 cells/well) or 12-well plates (26105 cells/well,
Biocoat; Becton Dickinson, Heidelberg, Germany) in William’s E
Medium (Gibco) containing 10% FCS (Gibco), 1% penicillin/
streptomycin and supplemented with cystein (90 mg/l) and
methionin (55 mg/l). Cells were stimulated after overnight
incubation. The JNK- and non-coding sequences used for siRNA
transfection have been described previously.25 For c-Jun the
following sequences were used. Sense: 59-AAAAAAGGAAGCT
GGAGAGAAT-39; antisense: 59-ATTCTCTCCAGCTTCCT
TT-39. For transient transfection Oligofectamine (Invitrogen,
Carlsbad, California, USA) was used according to the manu-
facturer’s instructions.
Reagents
SP600125 was purchased from Tocris (Bristol, UK) and dissolved in
dimethyl sulfoxide (DMSO). Anti-Apo1 antibody and LZCD95L
were a kind gift of P Krammer (DKFZ, Heidelberg, Germany).
TRAIL (Apo-2L, human recombinant) was purchased from Sigma
(Taufkirchen, Germany; cat. number K4761-20UG). The pancas-
pase inhibitor Z-VAD-FMK was purchased from Promega
(Mannheim, Germany), the caspase 8 inhibitor Z-IETD-FMK
and the caspase 9 inhibitor Z-LEHD-FMK were purchased from
BD Pharmingen (San Diego, California, USA); all were diluted in
DMSO and added at the concentration of 20 mmol/l.
Incubation of Chang cells with SP600125 also caused a G2/M
cell cycle arrest. Fluorescence-activated cell sorting (FACS)
analysis of DNA content showed a G2-phase cell cycle arrest
after 24 h of treatment with SP600125, compared to cells
treated with DMSO (p,0.005) (fig 1C).
Figure 2 (A–F) Light and fluorescence
microscopy features of Chang cells after
Hoechst staining (left and right panels,
respectively). Cells were analysed after
16 h incubation with TRAIL at the
concentration of 5 ng/ml in the presence
(A,B) or absence (C,D) of SP600125
(magnification, 6100). Cells were
washed, fixed in 6% formalin and stained
with 250 mg/ml Hoechst 33342 for 1 h
and then assessed by fluorescence
microscopy. (E) At higher magnification
(6400) typical morphological features of
cells undergoing apoptosis with
membrane blebbing and shrinkage.
(F) Chromatin condensation and nuclear
fragmentation (arrows) in comparison to
adjacent intact nuclei with Hoechst
staining of cells in panel (E).
TRAIL, tumour necrosis factor-related
apoptosis-inducing ligand.
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Apoptosis and membrane receptor assessment
Apoptosis and cell cycle were analysed by assessing sub-G1
events or the respective cell cycle phases in the euploid cell
fraction, using flow cytometry (FACScalibur, using Cell Quest
software; Becton Dickinson) according to Nicoletti et al.29
Additionally, apoptosis was assessed morphologically by
Hoechst 33342 staining (Sigma Chemical, Diesenhofen,
Germany) and fluorescence microscopy (Carl Zeiss, Jena,
Germany). The validity of FACS results in primary hepatocytes
was confirmed by comparing the number of apoptotic cells
observed after Hoechst staining (500 cells from four randomly
chosen fields per treatment group), with sub-G1 events
counted in FACS analysis. This comparison was done in
triplicate using cells from two different donors. For assessment
of membrane receptors, cells were detached from the plates by
ethylenediaminetetraacetic acid (EDTA), washed and incu-
bated for 1 h with the following monoclonal fluorescein
isothiocyanate (FITC)-coupled antibodies: CD95 (556640)
from BD Pharmingen, TRAIL-R1 (ALX-804-297F-T100),
TRAIL-R2 (ALX-522-005FC050) and control mIgG1 (Alexis,
San Diego, California, USA).
Western blot analysis
Briefly, proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS–PAGE) and transferred
to polyvinylidine difluoride (PVDF) membranes. After blocking
for 1 h in 5% milk–Tris-buffered solution(TBS)–Tween solu-
tion, membranes were incubated with primary antibodies at
4uC overnight, followed by the appropriate secondary antibody
for 1 h at room temperature. Bands were visualised using the
Figure 3 Sensitisation of hepatoma cells to apoptosis by SP600125 is a specific effect of JNK inhibition and is independent of cell line and p53 status.
(A,B) siRNA directed against JNK or control siRNA was transiently transfected into Chang cells. 105 cells were seeded in 12-well plates 24 h prior to
transfection in RPMI medium without antibiotics. Transfection was carried out in OptiMEM (Gibco) without FCS, which was added after 4 h. After 48 h,
anti-Apo1 (500 ng/ml) or TRAIL (5 ng/ml) were added for 16 h where indicated. (A) Western blot analysis of JNK expression; Optical density (o.d.)
expresses means and standard deviations of JNK versus actin of three different western blots. (B) FACS analysis by PI staining after JNK inhibition with
siRNA or non-coding siRNA. Apoptosis rates (sub-G1 fractions) represent mean and standard deviation from triplicate samples from the same experi-
ment; at least three other experiments gave similar results (*p,0.001). (C) 0.86105 HepG2 and Huh7 cells per well were seeded in 12-well plates.
After overnight incubation, cells were treated for 16 h with anti-Apo1 (500 ng/ml) or TRAIL (25 ng/ml) alone or in combination with SP600125 as
indicated. Graphs show mean apoptosis rates and standard deviation of one representative experiment, performed in triplicate, and repeated at least
three times. DMSO, dimethyl sulfoxide; FACS, fluorescence-activated cell sorting; FCS, fetal calf serum; JNK, cJun N-terminal kinase; PI, propidium
iodide; SP, SP600125; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
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ECL system (Amersham, UK). The following antibodies were
used: caspase 3 (Santa Cruz, H-277; Santa Cruz, California,
USA), JNK (Santa Cruz, D-2), phospho-c-Jun (ser63) II (Cell
Signaling, Beverly, New York, USA), c-Jun (BD Transduction),
actin (ICN Biomedicals, Irvine, California, USA). Densitometric
Figure 4 SP600125 inhibits TRAIL-R and CD95 mediated JNK
activation. (A–C) Fast activated cell-based ELISA (FACE) analysis of p-
JNK and JNK in Chang cells. Three thousand cells were seeded overnight
in 96-well plates. Cells were treated for 1 h with increasing TRAIL
concentrations (A). (B,C) Cells were treated with 5 ng/ml TRAIL, 100 ng/ml
anti-Apo1, DMSO or 20 mmol/l SP600125 (SP) for 0.5, 1, 3 or 5 h as
indicated. Relative absorption was calculated using crystal violet stain
to standardise for cell number of each sample according to the
manufacturer’s instructions (*values of TRAIL or anti-Apo1-treated
cells significantly increased versus baseline value; p,0.001).
(D) Western blot of p-JNK and JNK in unstimulated Huh7, HepG2 and
Chang hepatoma cells and primary hepatocytes (pH) from three
independent donors after overnight incubation. 35 mg of protein were
loaded in each lane. DMSO, dimethyl sulfoxide; JNK, cJun N-terminal
kinase; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
Figure 5 c-Jun inhibition enhances receptor mediated apoptosis.
(A) Downregulation of c-Jun by c-Jun specific siRNA (siJun) or control
non-coding siRNA (siCtrl) in HepG2 cells 24 h after transfection. Optical
density (o.d.) shows average and standard deviation vs actin of three
biological replicates. Upper panel shows inhibition of AP-1 transcriptional
activity as consequence of c-Jun downregulation as measured by
luciferase reporter assay. (B) Apoptosis rates after siRNA transfection
and 16 h of incubation with either CD95 ligand (10 ng/ml) or TRAIL
(2.5 ng/ml) in control-transfected cells vs c-Jun siRNA-transfected cells.
Apoptosis rates as measured by FACS after PI stain, are expressed as
mean, error bars indicating standard deviation of one representative
experiment, performed in triplicate and repeated at least three times
(*p,0.001 vs control). AP-1, activating protein-1; FACS, fluorescence-
activated cell sorting; PI, propidium iodide; TRAIL, tumour necrosis
factor-related apoptosis-inhibiting ligand.
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analysis was carried out using TINA software (Raytest,
Straubenhardt, Germany).
Fast activated cell-based ELISA (FACE)
The phospho-JNK FACE kit was purchased from Active Motif
(Carlsbad, California, USA). Three thousand cells per well were
seeded overnight in 96-well plates. Cells were stimulated as
indicated, then fixed in 4% formalin and plates were stored at
4uC. Incubation with primary and secondary antibody and
standardisation for cell count using in-well crystal violet stain
was done according to the manufacturer’s instructions.
Statistics
For statistical evaluation the t test for independent samples has
been used. Differences have been regarded as significant for p
values at least less than 0.05 and were indicated in each figure.
Unless otherwise specified, all values represent the mean and
standard deviation of triplicate values from the same
Figure 6 MAPK inhibition causes
increased recruitment of caspase 8 and
caspase 3. (A,B) Chang cells were treated
with 5 ng/ml TRAIL in the presence or
absence of SP600125. 50 mg of protein
were separated on 12% Bis/Tris minigels.
Fragments of cleaved caspase 3 (A) and
caspase 8 (B) are indicated. (C) Chang
cells were incubated and treated as in
fig 1; TRAIL was added at a concentration
of 5 ng/ml; anti-Apo1 at a concentration
of 100 ng/ml. Additionally, the
pancaspase inhibitor Z-VAD-FMK (PAN),
the caspase 8 inhibitor Z-IETD-FMK (aC8)
and the caspase 9 inhibitor Z-LEHD-FMK
(aC9) were added, each at a
concentration of 20 mmol/l (*each value
significantly lower vs cells treated with
the combination of SP600125 and TRAIL
or anti-Apo1, respectively, without
caspase inhibitors; p,0.001).
DMSO, dimethyl sulfoxide;
MAPK, mitogen-activated protein kinase;
SP, SP600125; TRAIL, tumour necrosis
factor-related apoptosis-inducing ligand.
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experiment, three or more experiments providing similar results
and significance levels. Calculations were performed by the
program Sigma Plot (SPSS, version 7.0).
RESULTS
JNK inhibition enhances receptor-mediated apoptosis and
causes cell cycle arrest
To evaluate the effects of JNK inhibition on receptor-mediated
apoptosis in hepatocellular carcinoma, we used Chang cells as a
model system. Cells were treated with TRAIL, the CD95
agonistic antibody anti-Apo1 or with the JNK inhibitor
SP600125 as indicated. The efficacy of SP600125 as JNK
inhibitor was confirmed by the inhibition of methyl methane
sulfonate (MMS)-induced c-Jun phosphorylation (fig 1A). While
Chang cells proved resistant to TRAIL, anti-Apo1 or to
SP600125 alone (fig 1A,B), addition of SP600125 synergistically
increased apoptosis rates triggered by TRAIL or anti-Apo1 (ie,
apoptosis increased from 7% to 55% after stimulation with
TRAIL at the concentration of 25 ng/ml). After 16 h of
incubation with SP600125 and TRAIL or anti-Apo1, Chang
cells displayed the characteristic morphological features of
apoptosis, such as cell shrinkage and membrane blebbing.
Hoechst staining of the same cells showed typical nuclear
fragmentation (fig 2A–F).
Sensitisation of hepatoma cells to apoptosis by SP600125 is a
specific effect of JNK inhibition and is independent of cell line
and p53 status
To rule out the possibility that the increased sensitivity to
apoptosis could be due to non-specific effects of SP600125 on
kinases other than JNK, we additionally targeted JNK by
specific interfering RNA sequences (fig 3A). JNK inhibition by
siRNA alone did not induce significant apoptosis, but clearly
increased the pro-apoptotic effect of TRAIL-receptor (TRAIL-R)
and CD95 stimulation (fig 3B). This confirms that JNK activity
does not affect basal apoptosis, but acts to suppress apoptosis
mediated by membrane receptors.
Similarly to the effect observed in Chang cells, the combina-
tion of SP600125 and anti-Apo1 or TRAIL also induced
apoptosis in HepG2 and Huh7 hepatoma cells (fig 3C). As
expected, due to the lack of a functional CD95 receptor in this
cell line, SP600125 only increased TRAIL-induced apoptosis, but
failed to enhance CD95-mediated apoptosis in Huh7.30 Thus, we
conclude that JNK inhibition sensitises hepatoma cells to
apoptosis, and is not cell-line specific. The fact that SP600125
greatly increases TRAIL sensitivity of Huh7 cells, which carry a
mutated p53, also shows that the effect of JNK inhibition on
apoptosis is not dependent on p53 status.
TRAIL-R- and CD95-mediated JNK activation represents a
negative feedback mechanism that interferes with receptor-
induced apoptosis in hepatoma cells
To assess the effect of the pro-apoptotic receptor stimulation on
JNK activity we used ELISA to measure the extent of JNK
activation in Chang cells, 1 h after stimulation with increasing
doses of TRAIL. As shown in fig 4A, stimulation of Chang cells
with TRAIL showed a dose-dependent increase of phosphoryla-
tion and thereby activation of JNK, while the total amount of
JNK remained unaffected (fig 4A). Subsequently, we also assessed
the time dependency of JNK activation and the total amount of
JNK by measuring phosphorylated JNK (p-JNK) levels at different
time points after stimulation. Incubation of Chang cells with 5 ng
TRAIL or 100 ng anti-Apo1 resulted in an early increase of p-JNK
levels which peaked after stimulation and progressively dimin-
ished over 5 h. Simultaneous administration of SP600125
effectively reduced TRAIL and anti-Apo1-induced JNK phosphor-
ylation (fig 4B), without affecting overall expression of JNK
(fig 4C). Thus, TRAIL-R- and CD95-mediated JNK activation is
likely to represent a negative feedback mechanism by which
hepatoma cells become resistant to receptor-induced apoptosis.
To evaluate whether the sensitivity to JNK inhibition is due to
JNK over-expression, and/or constitutive activation of JNK in our
in vitro system, the amount of p-JNK in Chang, HepG2 and Huh7
hepatoma cell lines was assessed by western blot in comparison to
that of primary cultivated hepatocytes. In agreement with data
from primary tumours,22 the level of p-JNK in the cell lines used in
our system was remarkably elevated in comparison to that
Figure 7 Surface expression of CD95 and TRAIL receptors in Chang cells after treatment with DMSO or SP600125. Surface staining of CD95, TRAIL-
R1 or TRAIL-R2 was performed 24 h after stimulation. In comparison to an isotype-matched control mIgG1 monoclonal antibody (thin line), receptor
expression of cells treated with SP600125 alone are shown as a bold line; cells treated with DMSO as a shaded area. CD95 and TRAIL-R2 but not
TRAIL-R1 were significantly downregulated in SP600125-treated cells versus DMSO-treated cells. The data represent one of at least three independent
experiments with similar results. Significance levels of each receptor expression versus DMSO-treated cells are reported. DMSO, dimethyl sulfoxide;
NS, not significant; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
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observed in primary hepatocytes from three different donors
(fig 4D).
c-Jun inhibition enhances receptor mediated apoptosis
To investigate whether JNK exerts its anti-apoptotic affect
through activation of c-Jun and AP-1 transcriptional activity24
we also targeted c-Jun with specific RNA interference. siRNA
transfection of HepG2 cells with c-Jun siRNA effectively
decreased c-Jun at the protein level (fig 5A). RNA interference
also led to a 10-fold decrease of the AP-1 transcription activity,
as determined by reporter luciferase activity 24 h after
transfection (fig 5A). siRNA transfection, application of
10 ng/ml of the CD95 ligand (LZCD95L) or of 2.5 ng/ml
TRAIL for 16 h did not significantly affect apoptosis rates.
However, apoptosis greatly increased up to 64% and 69% when
the CD95 ligand or TRAIL were administered in cells pre-
viously transfected with c-Jun-targeting siRNA (fig 5B). Thus,
inhibition of c-Jun resulted in a similar pro-apoptotic effect as
inhibition of JNK suggesting that c-Jun/AP-1 transcriptional
activity contributes to the pro-apoptotic effect observed after
JNK inhibition.
Inhibition of MAPK facilitates receptor-mediated activation of
caspase 8, independently of membrane receptor expression
To determine the level of interaction between JNK inhibition
and the receptor-mediated pro-apoptotic pathway, caspase
cleavage was assessed. Co-treatment of Chang cells with
SP600125 and TRAIL or anti-Apo1 increased activation of both
caspase 3 and 8. Early appearance of cleaved fragments of
caspase 8 demonstrates that caspase 8 activation is an early
event in the induction of apoptosis, and not a feedback
phenomenon occurring at later time points (fig 6A,B). To
further investigate the interaction between JNK and caspase
activation we analysed the effects of several caspase inhibitors
Figure 8 JNK inhibition does not affect
TRAIL-mediated apoptosis in primary
hepatocytes. Primary hepatocytes were
treated with anti-Apo1 (A) TRAIL (B) in
combination with SP600125 (20 mmol/l)
or DMSO as indicated. 105 cells/well were
seeded in collagen-coated 12-well plates.
Values represent cell viability, as
measured by FACS, non-treated cells
being set to 100%. Average and standard
deviation values are representative of
values obtained from three different
independent donors ({ not significant).
(C–F) Light and fluorescence microscopy
features of primary hepatocytes after
Hoechst staining (left and right panels,
respectively). Cells were harvested after
24 h incubation with TRAIL in
combination with DMSO (C,D) or
SP600125 (E,F; magnification, 6100).
DMSO, dimethyl sulfoxide;
FACS, fluorescence-activated cell sorting;
JNK, cJun N-terminal kinase;
TRAIL, tumour necrosis factor-related
apoptosis-inducing ligand.
Hepatology
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on the synergistic effect of SP600125 and TRAIL or anti-Apo1.
The pancaspase inhibitor Z-VAD-FMK abolished any apoptotic
effect of TRAIL and anti-Apo1, even when combined with
SP600125. A similar effect could be observed after administra-
tion of the caspase 8 inhibitor Z-IETD-FMK. Incubation with
the caspase 9 inhibitor Z-LEHD-FMK also significantly reduced
apoptosis rates triggered by combined treatment of Chang cells
with SP600125 and TRAIL or anti-APO1 (fig 6C). This clearly
demonstrates that increased recruitment of caspase 8 after
TRAIL-receptor or CD95 stimulation is an essential mechanism
by which JNK inhibition sensitises hepatoma cells to apoptosis.
The fact that caspase 9 activation also contributes to TRAIL and
anti-Apo1-induced apoptosis after JNK inhibition is in agree-
ment with the notion that hepatocytes are type 2 cells, ie, are
capable of reinforcing apoptotic signalling initiated by the
membrane receptors through the recruitment of the mitochon-
drial pathway.
Since loss of membrane receptors plays a role in carcinogen-
esis,31 32 and several chemotherapeutic drugs have been shown to
increase expression of death receptors,33 we assessed whether
the increased caspase 8 recruitment observed after JNK/Jun
inhibition could be due to an increase of surface receptor
expression. As judged by FACS analysis, treatment with
SP600125 did not lead to an increase of membrane receptors.
Instead, a significant decrease of CD95 and TRAIL-R2 (fold
decreases of 0.69 (SD 0.1) and 0.58 (SD 0.1), respectively;
p,0.05), but not of TRAIL-R1 could be detected (fig 7). This
indicates that JNK inhibition sensitises hepatoma cells to
apoptosis by affecting the intracellular apoptotic signalling
pathways.
Inhibition of JNK does not sensitise primary human hepatocytes
to receptor-mediated apoptosis
To assess whether the effect of JNK inhibition is specific for
cancer thus representing a feasible therapeutic option for HCC,
we also evaluated the effect of JNK inhibition on sensitivity to
TRAIL of normal cells. To this end, primary normal human
hepatocytes, cultivated for 1 day after liver perfusion, were
incubated with anti-Apo1 or TRAIL in the presence or absence
of SP600125. As reported previously,9 hepatocytes proved highly
sensitive to CD95 stimulation (fig 8A). In contrast, a
concentration of 5 ng/ml of TRAIL only marginally reduced
cell viability. In both cases, concomitant JNK inhibition by
SP600125 did not increase apoptosis (fig 8B) as judged by FACS
analysis, morphological features of cells and Hoechst nuclear
staining (fig 8C–F). JNK activity therefore strongly influenced
the sensitivity to apoptosis inducing surface receptors cancer
cells, but not in normal cells.
Sensitivity of primary mouse hepatocytes to receptor-mediated
apoptosis is independent of c-Jun phosphorylation and JNK
activity
Since no specific pharmacological inhibitor of c-Jun is available
to assess the effect of the mitogen-activated protein kinase
(MAPK) inhibition downstream of JNK, we compared the
sensitivity to CD95 stimulation in hepatocytes isolated from
wild-type mice with that of hepatocytes obtained from mice
carrying a mutation at the site of c-Jun phosphorylation (JunA/
A).28 Confirming that c-Jun phosphorlyation does not affect
CD95-mediated cell death in normal cells, basal apoptosis rates
in hepatocytes isolated from JunA/A mice did not differ from
that observed in cells isolated from wild-type mice. Moreover,
administration of the murine CD95 agonistic antibody Jo-2
Figure 9 Sensitivity of isolated primary mouse hepatocytes is
independent of c-Jun phosphorylation or JNK activity. (A,B) 2.06105
hepatocytes, isolated from mice expressing the mutated form of c-Jun
lacking the activating phosphorylation site (AA) or wild-type (wt) mice
were seeded in collagen-coated 12-well plates and allowed to attach for
2 h. Apoptosis rates were determined by measuring sub-G1 events using
FACS analysis 16 h after stimulation. The graph shows mean apoptosis
rates and SD of one representative experiment, performed in triplicate,
and repeated at least three times. (A) Apoptosis rates in hepatocytes
isolated from A/A mice and from wild-type after incubation with 100 ng/ml
of the mouse CD95 agonistic antibody Jo-2 for 16 h or incubated with
medium alone. (B) Apoptosis rates in wild-type hepatocytes after
stimulation with Jo-2 alone or in combination with SP600125.
(C) Apoptosis rates of HepA1-6 mouse hepatoma cells, 16 h after
treatment with SP600125, Jo-2 or a combination of both (*p,0.01;
{NS). DMSO, dimethyl sulfoxide; JNK, cJun -N-terminal kinase;
SP, SP600125.
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triggered apoptosis in hepatocytes from JunA/A mice at the
same rate as in wild-type hepatocytes (fig 9A). JNK inhibition
by SP600125 also did not affect apoptosis rates (fig 9B). Failure
to sensitise mouse cells was not due to a species specific effect of
SP600125 in human cells, because SP600125 greatly sensitised
HepA1-6 mouse hepatoma cell line to the action of Jo-2 (fig 9C).
DISCUSSION
JNK is constitutively active in many tumours and in as many as
75% of hepatocellular carcinomas. The mechanism by which
this kinase contributes to the carcinogenesis of tumours,
however, still remains largely an object of debate19 34 35 We
show here how inhibition of JNK affects proliferation and
apoptotic properties of hepatocellular carcinoma cells, making
the targeting of this signalling pathway a potential target for
the treatment of these tumours.
TRAIL exerts a primary role in the surveillance of tumour
formation as demonstrated by several animal models as well as
clinical data. We also recently reported that the over-expression
of OPG, a decoy receptor for TRAIL regulated by b-catenin, in
patients affected by colorectal carcinoma correlates with
tumour stage and metastasis formation.5
In our system JNK inhibition caused cell cycle arrest and
sensitised cancer cells to TRAIL-mediated apoptosis. TRAIL
administration resulted in the increase of JNK activity and this
effect could be reverted by administration of SP600125. This
suggests that early JNK activation upon TRAIL administration
represents a negative feedback mechanism of apoptosis inhibi-
tion in cancer cells. It is therefore likely that the frequently
observed over-expression of JNK in cancer cells24 results from
the selection of clones resistant to endogenous TRAIL following
a gain of function of JNK as negative regulator of apoptosis. The
association of SP600125 and TRAIL synergised to induce
apoptosis selectively in cancer cells. Thereby anti-tumour
concentrations of TRAIL could be tapered to low doses. Thus,
JNK inhibition might also improve both efficacy and safety of
TRAIL administration for therapeutic purposes.
Treatment of Chang cells with SP600125 led to increased
recruitment and activation of caspase 8 upon the stimulation of
the death receptors. However, increased caspase 8 recruitment
was not due to an increase of the quota of TRAIL receptor or
CD95 on the cell membranes. Expression of TRAIL-R1, TRAIL-
R2 and CD95 on the cell surface was not increased as a
consequence of JNK inhibition; instead, a decrease of TRAIL-R2
and of CD95 could be detected (fig 7).
Our findings describing an anti-apoptotic role for JNK are in
contrast to previous data showing that JNK can also act as
mediator of apoptosis: prolonged JNK activation has been
shown to be the essential mediator of cell death in response to
TNF and oxidative stress in non-transformed cells.19 20
Furthermore, several publications showed recently that JNK
might act pro-apoptotically, mediating cell death triggered by
TRAIL in diseased, non-transformed hepatocytes as a conse-
quence of several pathological situations such as adenoviral
hepatitis,36 hepatitis C virus hepatitis,37 cholestatic liver disease38
and non-alcoholic steatohepatitis.39
Our finding that JNK inhibition acts to enhance apoptosis in
liver tumours suggests that JNK in the liver might have different
roles in non transformed cells under stress conditions14 19 20 and
in cancer cells.
A different effect of JNK inhibition in cancer cells and in non-
tumour cells is likely to have relevant clinical significance: liver
cancer arises in most cases in the context of a diseased
liver where JNK, as shown by the aforementioned papers, acts
pro-apoptotically to mediate TRAIL toxicity. Use of JNK
inhibitors to sensitise cancer cells to TRAIL might open the
way for the use of TRAIL in the therapy of liver tumours, since
their use may reduce liver damage and TRAIL toxicity in non-
tumour tissues while sensitising malignant cells to TRAIL.
Remarkably, in many of the recent works investigating the
mechanism of TRAIL toxicity in non-tumour cells showed that
the pro-apoptotic effect of TRAIL was mediated in these cells by
increased TRAIL-R2 in adenoviral hepatitis,36 bile-acid-induced
TRAIL sensitisation38 and in liver steatosis;39 this is in agreement
with the fact that in our system JNK inhibition reduced the
expression of TRAIL-R2 and of CD95 but not that of TRAIL-R1
(fig 7); however, reduction of TRAIL-R2 did not impair the pro-
apoptotic effect of TRAIL in cancer cells, suggesting that JNK
might act to reduce TRAIL toxicity in normal cells by decreasing
the amount of TRAIL receptors on the cell membranes while
sensitising cancer cells by enhancing the intracellular signalling
of TRAIL.
Inhibition of JNK signalling effectively sensitised tumour cells
to TRAIL independently of the tumour suppressor p53 (fig 3).
Mutations of p53 occur in approximately 50% of all human
tumours40 and represent a major cause of tumour resistance to
therapy.41 Therefore inhibition of the MAPK signalling pathway
combined with administration of TRAIL could overcome
frequent mechanisms of resistance to traditional chemotherapy.
In summary, these data shed new light on how the frequent
hyperactivation of JNK in HCC is likely to contribute to
carcinogenesis by causing resistance to endogenous TRAIL.
Also, JNK inhibition promises to address the problems bound to
the exogenous administration of TRAIL for therapeutic
purposes by sensitising cancer cells to receptor-mediated
apoptosis and by reducing its potential toxicity by decreasing
the concentrations needed to trigger apoptosis in cancer cells.
JNK inhibition might furthermore increase intrinsic resistance
of non-transformed cells to TRAIL.
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